These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

758 related articles for article (PubMed ID: 26581749)

  • 1. Overview of Data Concerning the Safe Use of Antihyperglycemic Medications in Type 2 Diabetes Mellitus and Chronic Kidney Disease.
    Roussel R; Lorraine J; Rodriguez A; Salaun-Martin C
    Adv Ther; 2015 Nov; 32(11):1029-64. PubMed ID: 26581749
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Complementing insulin therapy to achieve glycemic control.
    Barnett AH
    Adv Ther; 2013 Jun; 30(6):557-76. PubMed ID: 23797471
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glycemic control of type 2 diabetes mellitus across stages of renal impairment: information for primary care providers.
    Tong L; Adler S
    Postgrad Med; 2018 May; 130(4):381-393. PubMed ID: 29667921
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetic considerations for the treatment of diabetes in patients with chronic kidney disease.
    Scheen AJ
    Expert Opin Drug Metab Toxicol; 2013 May; 9(5):529-50. PubMed ID: 23461781
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetic and toxicological considerations for the treatment of diabetes in patients with liver disease.
    Scheen AJ
    Expert Opin Drug Metab Toxicol; 2014 Jun; 10(6):839-57. PubMed ID: 24669954
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardiovascular benefits and safety of non-insulin medications used in the treatment of type 2 diabetes mellitus.
    Yandrapalli S; Jolly G; Horblitt A; Sanaani A; Aronow WS
    Postgrad Med; 2017 Nov; 129(8):811-821. PubMed ID: 28749197
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Newer anti - diabetic therapies and chronic kidney disease].
    Di Lullo L; Ronco C; Barbera V; Cozzolino M; Santoboni F; Villani A; De Pascalis A; Bellasi A
    G Ital Nefrol; 2017; 34(1):. PubMed ID: 28177092
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel hypoglycaemic agents: considerations in patients with chronic kidney disease.
    Game F
    Nephron Clin Pract; 2014; 126(1):14-8. PubMed ID: 24434725
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacologic Management of Type 2 Diabetes Mellitus: Available Therapies.
    Thrasher J
    Am J Cardiol; 2017 Jul; 120(1S):S4-S16. PubMed ID: 28606343
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics and clinical use of incretin-based therapies in patients with chronic kidney disease and type 2 diabetes.
    Scheen AJ
    Clin Pharmacokinet; 2015 Jan; 54(1):1-21. PubMed ID: 25331711
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metformin and other antidiabetic agents in renal failure patients.
    Lalau JD; Arnouts P; Sharif A; De Broe ME
    Kidney Int; 2015 Feb; 87(2):308-22. PubMed ID: 24599253
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Network meta-analysis of treatments for type 2 diabetes mellitus following failure with metformin plus sulfonylurea.
    Lozano-Ortega G; Goring S; Bennett HA; Bergenheim K; Sternhufvud C; Mukherjee J
    Curr Med Res Opin; 2016 May; 32(5):807-16. PubMed ID: 26700585
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Management of Diabetes Mellitus in Patients With CKD: Core Curriculum 2022.
    Hahr AJ; Molitch ME
    Am J Kidney Dis; 2022 May; 79(5):728-736. PubMed ID: 34600745
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Newer Pharmacologic Treatments in Adults With Type 2 Diabetes: A Systematic Review and Network Meta-analysis for the American College of Physicians.
    Drake T; Landsteiner A; Langsetmo L; MacDonald R; Anthony M; Kalinowski C; Ullman K; Billington CJ; Kaka A; Sultan S; Wilt TJ
    Ann Intern Med; 2024 May; 177(5):618-632. PubMed ID: 38639549
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Selection and dosing of medications for management of diabetes in patients with advanced kidney disease.
    Reilly JB; Berns JS
    Semin Dial; 2010; 23(2):163-8. PubMed ID: 20210915
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of second-line antihyperglycemic drugs on the risk of chronic kidney disease: applying a target trial approach to a hospital-based cohort of Thai patients with type 2 diabetes.
    Siriyotha S; Lukkunaprasit T; Looareesuwan P; Nimitphong H; McKay GJ; Attia J; Thakkinstian A
    Cardiovasc Diabetol; 2022 Nov; 21(1):248. PubMed ID: 36397062
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antidiabetic agents in patients with chronic kidney disease and end-stage renal disease on dialysis: metabolism and clinical practice.
    Abe M; Okada K; Soma M
    Curr Drug Metab; 2011 Jan; 12(1):57-69. PubMed ID: 21303332
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiovascular Effects of Glucose-lowering Therapies for Type 2 Diabetes: New Drugs in Perspective.
    Thompson PL; Davis TME
    Clin Ther; 2017 May; 39(5):1012-1025. PubMed ID: 27863704
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment choices for the glycaemic management of patients with type 2 diabetes and chronic kidney disease: Analysis of the SAIL patient linked dataset.
    Min T; Davies GI; Rice S; Chess J; Stephens JW
    Diabetes Metab Syndr; 2018; 12(2):123-127. PubMed ID: 29239764
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiovascular Protection in the Treatment of Type 2 Diabetes: A Review of Clinical Trial Results Across Drug Classes.
    Paneni F; Lüscher TF
    Am J Med; 2017 Jun; 130(6S):S18-S29. PubMed ID: 28526186
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 38.